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Abstract: In Kaposi’s sarcoma-associated herpesvirus (KSHV) oncogenesis, both 
latency and reactivation are hypothesized to potentiate tumor growth. The KSHV Rta 
protein is the lytic switch for reactivation. Rta transactivates essential genes via interactions 
with cofactors such as the cellular RBP-Jk and Oct-1 proteins, and the viral Mta protein. Given 
that robust viral reactivation would facilitate antiviral responses and culminate in host cell 
lysis, regulation of Rta’s expression and function is a major determinant of the latent-lytic 
balance and the fate of infected cells. Our lab recently showed that Rta transactivation 
requires the cellular peptidyl-prolyl cis/trans isomerase Pin1. Our data suggest that 
proline-directed phosphorylation regulates Rta by licensing binding to Pin1. Despite Pin1’s 
ability to stimulate Rta transactivation, unchecked Pin1 activity inhibited virus production. 
Dysregulation of Pin1 is implicated in human cancers, and KSHV is the latest virus known 
to co-opt Pin1 function. We propose that Pin1 is a molecular timer that can regulate the 
balance between viral lytic gene expression and host cell lysis. Intriguing scenarios for 
Pin1’s underlying activities, and the potential broader significance for isomerization of 
Rta and reactivation, are highlighted.  
Keywords: Kaposi’s sarcoma-associated Herpesvirus; Human herpesvirus-8; herpesvirus; 
reactivation; Rta; transcriptional activation; Pin1; Peptidyl-prolyl cis/trans isomerase 
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1. Kaposi’s Sarcoma-Associated Herpesvirus Latency and Reactivation: A Primer 
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is 
a large double-stranded (ds) DNA virus [1–5]. KSHV causes Kaposi’s sarcoma (KS), an 
AIDS-defining malignancy, and primary effusion lymphoma (PEL). Despite its discovery twenty years 
ago, it remains the most recently-identified human herpesvirus. KSHV is a Rhadinovirus, or 
γ2-herpesvirus, classified together with MHV-68, HVS and rhesus rhadinovirus (RRV) [2,6]. 
KSHV diverged from Lymphocryptovirus or γ1-herpesviruses, such as Epstein-Barr Virus (EBV), 
circa 100,000 years ago in Africa [4]. The KSHV virion is enveloped and glycoprotein-studded, 
with large, ~120 nm icosahedral capsids [2–4,7,8]. Inside the envelope lies the tegument, an 
amorphous structure comprised of a multitude of viral and host proteins, although the functions of 
many remain unknown [2–4,9]. Inside the tegument lies the capsid that contains the embedded, 
linear viral genome [3,4].  
The HHV-8 genome is variable in length, usually reported as between 160–170 kb [1–5,8]. Of this, 
145 kb comprises unique sequence, while the remaining variable portion is derived of guanine-
cytosine (GC)-rich terminal repeats (TRs) that flank the genomic ends [1,2,4,10]. Genomes contain 
~87 open reading frames (ORFs) capable of encoding well over 100 functional gene products, a set of 
15 KSHV-unique “K” genes, up to ~25 unique viral microRNA (miRs) and a highly expressed 
noncoding transcript (nut-1, also known as polyadenylated nuclear RNA [PAN]) [1–5,10]. A large 
number of viral proteins are also involved in pathogenic functions within host cells, including for cell 
proliferation, paracrine signaling, immune suppression and inhibition of apoptosis [2,3,5]. 
Like all herpesviruses, KSHV can undergo two alternative, essential gene expression programs 
throughout its lifecycle: latency and lytic replication [2–4]. In nearly all infected cells, latency, defined 
by the absence of mature virus production, predominates within 24–48 h after initial infection [2–4]. 
Once adopted, the nonproductive latency program is characterized by constitutive expression of a 
small subset of KSHV genes, many of which are localized to a single locus [2,4,10]. The program is 
well documented to occur in both virus-harboring KS spindle cells and PEL cells [2–4,10–14]. 
While latency is the default state of KSHV, a small subpopulation of infected cells, usually 1% to 
5%, support spontaneous lytic reactivation [2–4,7,10,14,15]. The lytic cycle is essential for production 
of progeny virus that can then disseminate and infect other cells and other individuals through 
shedding [2–4,7,10,14,15]. While virion production is the ultimate step in reactivation, it is by no means 
the predestined outcome. Sometimes, lytic reentry is abortive, or “sublytic,” and does not proceed to 
virion assembly and release [1,2,4,7,16]. This is because the herpesviral lytic cycle is regulated at several 
stages. Lytic reactivation can be thought of as a multistep cascade consisting of five broad kinetic 
intervals: immediate-early (IE) viral gene expression; delayed-early (DE) gene expression; viral DNA 
replication; late gene (L) expression; and finally virion production [2–4,7,10,14,17].  
IE genes express a few viral transcription factors such as the lytic switch Rta (ORF50), which 
then activate the expression of DE genes, many of which are lytic cycle-specific K genes [2,4,7,17,18]. 
Notably, KSHV is unique among human herpesviruses in that many of these lytic K proteins, and other 
DE proteins, are mimics of cellular proto-oncoproteins and cytokines [2,4,5,9,15,17,18]. After initiation 
of viral DNA replication, late gene production begins [2–4,7,14,17]. These mostly comprise the 
aforementioned capsid, tegument and envelope proteins required for virion assembly [2,4,9]. It is not 
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currently understood how late gene synthesis is regulated by viral DNA replication itself, 
independently of DE gene expression. Replication-dependent epigenetic regulation, such as histone 
modification, is among the possibilities [7,19–21]. Envelopment leads to maturation of virions, 
complete with decoration of envelopes with viral glycoproteins, such as K8.1 [3,4,22,23]. It is currently 
thought that infected B cells, the viral reservoir, release virions that can then disseminate to the lymphatic 
endothelium and seed for KS tumor development [2,4]. 
Lytic reactivation has been widely accepted in the literature as not just important for dissemination 
of infectious virus, but also as fundamental to tumorigenesis directly, a contention that is  
supported by animal models [2–4,7,8,10,11,13,15,23–29]. The virus may complement its latent  
tumorigenic potential by expression of the DE oncoproteins, some of which have transforming 
properties alone in vitro and in infected cells [2,24,30–32]. It is hypothesized that the secretion of 
paracrine factors, such as cytokines and growth factors, during the lytic cycle serves to stimulate the 
surrounding tumor microenvironment of uninfected and latently-infected cells for further growth and 
survival [2,4,10,11,15,33]. 
2. Function and Regulation of Rta Lytic Switch Protein 
Replication and transcription activator (Rta) is a 691 amino acid (aa) IE transcription factor encoded 
from the major IE locus tricistronic transcript [2,34,35]. Its transcript is among the first produced 
following chemical induction by 12-O-tetradecanoyl phorbol-13-acetate (TPA), being expressed 
within 1 hpi [2,17,34]. This gene alone was identified to encode the lytic switch protein of KSHV,  
and is necessary and sufficient for the onset of productive lytic reactivation, with concomitant release 
of infectious virions [2,4,7,34,35]. Rta’s function was confirmed via observations that ectopic Rta 
induced reactivation alone in infected B cells, as well as by functional binding analyses with truncation 
and dominant negative (DN) mutants and by genetic analyses with Rta-deficient viral bacmid-infected 
cells, both of which were incapable of reactivation [2,7,35–37]. Further, addition of TPA could not 
induce the Rta-deficient virus, but induction was rescued by ectopic Rta expression [36]. Rta also 
autoactivates its own promoter, an activity characteristic of protein switches [7,37–39].  
Both Rta and basic leucine zipper K-bZIP (K8) are syntenic orthologs of EBV transcriptional 
transactivators Rta (BRLF1, 20%) and Zta (BZLF1, 22%), respectively [7,34,37,40]. While KSHV Rta 
is alone required for viral reactivation through its transactivation activity at downstream viral 
promoters, both EBV transactivators are necessary for the EBV lytic program, in which they function 
independently and synergistically at different subsets of viral promoters [7,37,40,41]. K-bZIP, 
meanwhile, despite a homology to Zta and its role in gene expression, could not reactivate KSHV or 
transactivate viral genes alone [4,7,37,41].  
Rta protein has an apparent molecular weight of 73.7–120 kilodalton (kDa), a difference indicative 
of its extensive posttranslational modifications, predominantly phosphorylation (20 kDa  
alone) [7,34,37,42–44]. Rta is also ADP-ribosylated [45], and may contain other modifications. Rta 
encodes a multitude of structural and functional domains: an N-terminal DNA-binding domain (DBD), 
C-terminal transactivation domain (TAD), basic amino acid-rich region, proline-rich regions, 
serine/threonine-rich region, cysteine/histidine-rich region, hydrophobic-acidic repeat region, leucine 
heptapeptide repeat domain, two nuclear localization signals (NLSs) and dimerization and 
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tetramerization domains, in addition to a variety of sites and regions important for interactions with 
viral and cellular proteins (Figure 1) [2,4,7,37,40,46]. Removal of Rta’s TAD, which resembles a 
domain in viral protein (VP) 16 of herpes simplex virus 1 (HSV-1), results in a DN mutant 
(RtaΔSTAD) incapable of transactivation alone; this will be discussed further below [7,35,37,47].  
 
Figure 1. Rta/ORF50 primary amino acid structure/function map. A linear representation 
of the primary structure and predicted regions and interactions of Rta protein. Numbers 
refer to aa position. Locations of each domain are shown by the colored bars, with 
functional boundaries indicated by aa, corresponding to the activity or interacting protein 
listed in the column at right. Numbers in parentheses indicate references. Color codes for 
bars are: black, core functional domain; red, Rta inhibitor; green, Rta stimulator. Citations 
are listed in parentheses, and described in the text. +++, basic amino acid rich; LR, leucine 
heptapeptide repeat domain; ST, serine/threonine-rich; hyd/DE/hyd, repeats of 
hydrophobic and acidic amino acids, comprising Rta’s transactivation domain (TAD); 
NLS, nuclear localization sequence; Dom. Neg., dominant negative. Figure and legend 
modified from [37].  
2.1. Mechanisms of Rta-Mediated Transactivation 
While Rta is both necessary and sufficient for viral reactivation, its transactivation activity is 
inefficient. This is underscored by reports demonstrating that Rta activity alone, in the absence of 
ongoing cellular or viral protein production, is unable to induce the full repertoire of lytic  
genes [7,16,37,46,48–51]. Rta’s inefficiency is also supported by data showing that Rta is weakly or 
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nontransactive when mutated to prevent binding of specific cofactors, or when cofactor binding motifs 
in promoters are disrupted [7,16,37,39,46,47,49,52–55]. Finally, Rta expression does not necessarily 
translate into productive replication in infected cells, as typically fewer than 20% of Rta-positive PEL 
cells coexpress true late protein K8.1 (produced only following viral replication, and often utilized as a 
reactivation marker) [37,50]. The implications of these findings, are twofold. First, that Rta requires 
viral and cellular protein interactions to guide it through the full lytic cascade, via direct binding, 
posttranslational modifications or both. Second, that the conserved inefficiency of Rta lytic switch 
function may be important for KSHV pathogenesis.  
Rta’s transcription at downstream gene promoters is highly complex. In broad terms, and with 
exceptions, specificity to target promoters can be characterized as either direct or indirect, and as 
independent or dependent on interaction with the Notch signaling pathway effector recombination 
signal binding protein (RBP-Jk, which will be discussed below) [2,4,7,37–39,46,55,56].  
Direct transactivation occurs by Rta binding to Rta-responsive elements (RREs) within certain 
promoters [4,37,38,46,55–58]. RREs, both RBP-Jk-dependent and -independent, can vary 
significantly, but four general consensus sequences have so far been uncovered: the palindromic repeat 
TTCCAGGAT(N)TTCCTGGGA, where N represents as many as sixteen random bases; multiple units 
of an A/T trinucleotide repeat, found in the K-bZIP, DE gene Mta and glycoprotein-encoding gene K1 
promoters; recently-identified, TATA-box proximal elements known as “CANT DNA repeats” 
(discussed below); and the interferon (IFN) stimulated response element (ISRE)-like motif 
(A/G)NGAAANNGAAACT, found in promoters for vIL-6, vGPCR and ORF8 [37,38,46,55,56]. 
Binding to the latter depends on partial homology of Rta’s DBD to IRF family members [37,46]. 
Meanwhile, Rta binding affinity is largely proportional to the extent of transactivation for  
RBP-Jk-independent promoters [7,37]. The prototypical genes are kaposin and nut-1, with Rta binding 
at the nut-1 promoter with nanomolar (nM) affinity, and with nut-1 being the most abundant transcript 
produced during the lytic cycle [2,35,37,53,59,60]. Direct Rta transactivational targets have been 
identified by several labs. One such screen from our lab reported eight direct targets, including the 
promoters for nut-1, Mta, viral interleukin (vIL)-6, viral shutoff exonuclease (vSOX) and vOX2 [57]. 
Additional promoters, such as ORF45 and the miRNA locus, have also been described, though use of 
different methods and cell lines makes confirmation of authentic direct promoters difficult [37,38,56]. 
Finally,Rta also can bind DNA combinatorially with cellular or viral cofactors, such as octamer 1 
(Oct1) and others, or enhance their transactivation, such as CREB binding protein (CBP); these are 
discussed below [4,37,39,46,52].  
2.2. Rta Positively and Negatively Interacts with Host and Viral Cofactors 
Rta is involved in a host of other important lytic cycle functions beyond its primary role as a 
transcription factor. For one, viral DNA replication is unable to proceed without Rta activity at  
oriLyts [7,37,61]. There, Rta binds to RREs as an origin binding protein in conjunction with K-bZIP 
and CCAAT/enhancer binding protein (C/EBP)-α (which itself has palindromic motifs within  
oriLyts) [37,55,61]. Together, these proteins recruit the core replication machinery to viral genomic 
DNA [7,61]. Rta also inhibits p53 transcription via a direct interaction with CBP, and modulates both 
IFN regulatory factor (IRF)7 and cellular K-Rta binding protein (K-RBP) stability via Rta’s E3 
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ubiquitin ligase (Cys/His-rich) domain [62–66]. Rta ubiquitylates the Notch and hypoxia response 
pathway target protein Hey1, a transcriptional repressor that may be involved in cell differentiation; it 
has been further suggested, but not confirmed, that Rta can destabilize latency-associated nuclear 
antigen (LANA)-1 and K-bZIP [7,46,64,67,68]. Rta’s ubiquitylation of some of the above proteins is in 
response to their own repressive function against Rta; in fact, multiple factors positively and negatively 
regulate Rta expression and activity for tight control over reactivation from latency.  
A number of antagonistic factors stem from viral latency itself. LANA, for instance, is capable of 
repressing Rta at multiple levels. LANA inactivates transcription from the ORF50 promoter  
directly, as well as indirectly, by competitive binding with cofactors CBP and RBP-Jk to prevent  
Rta-mediated autoactivation [4,7,14,46,69–73]. LANA also may recruit histone deacetylases  
(HDACs) and specificity protein 1 (Sp1) for similar repression from their motifs in the Rta  
promoter [2,4,14,20,52,71,73,74]. LANA acts directly on Rta protein to prevent Rta autoactivation 
[2,4,7,70]. Two miRs directly target the 3' untranslated region (UTR) of Rta mRNA for degradation 
[75–78]. vFLIP can repress Rta transactivation activity, as well as Rta’s own transcription through its 
effects on nuclear factor of kappa B (NF-B) [7,79]. vFLIP mediates this repression in at least two 
ways. First, through NF-B’s competition with, and sequestration of, RBP-Jk for DNA binding and  
for Rta protein association, respectively [7,14,80]. Second, through inhibition of the activating  
protein (AP)-1 pathway, blocking Rta expression [79,81]. As AP-1 binding sites are found in both  
the promoters of Rta and downstream genes as well as in oriLyts, repression of AP-1 transactivation 
likely affects both Rta expression and functions as a transcription factor and DNA replication  
regulator [7,37,61,81]. 
Cellular and viral lytic cycle proteins also modulate Rta [37,82–84]. In addition to HDAC and Sp1, 
K-RBP and IRF7 block Rta transactivation activity, the former through an additional interaction with 
cellular transcription intermediary factor 1β (TIF1β), which are thought to bind to specific promoter 
DNA elements and block Rta function (K-RBP) or compete for Rta DNA-binding (IRF7) [7,63–65]. 
Meanwhile, poly(ADP-ribose) polymerase 1 (PARP1) and human kinase from chicken (hKFC) bind 
directly to Rta protein’s Ser/Thr-rich domain to modify Rta through ribosylation and phosphorylation, 
respectively, inhibiting Rta transactivation [45]. Rta-modulating phosphorylation is also induced by the 
proliferation and apoptosis regulator Akt (also known as protein kinase B) of the PI3K pathway [7,85]. 
Finally, K-bZIP, a cofactor with Rta for initiation of viral replication at oriLyts, also inhibits Rta 
transactivation of selective viral promoters, including for nut-1, Mta and K-bZIP itself, by directly 
binding to Rta [2,4,7,37,67]. K-bZIP is also known to bind and repress CBP, which might disrupt Rta 
expression and function [4,7,67].  
Thus, also, do multiple proteins, beyond K-bZIP in the context of DNA replication, enhance Rta’s 
expression and functions. For instance, Pim1 and Pim3, proto-oncoproteins involved in cell cycle and 
apoptotic pathways, upregulate Rta autoactivation by binding to and repressing LANA’s inhibition of 
the Rta promoter [86]. Viral G protein coupled receptor (vGPCR) may also negate LANA inhibition 
by reducing HDAC activity to allow for Sp1- and Sp3-dependent Rta promoter activity [87,88]. 
Hypoxia inducible factor (HIF)-1α can directly activate the Rta promoter, due to the presence of 
several putative hypoxic response elements (HREs) [69,89,90]. Interestingly, LANA was reported to 
activate Rta transcription through binding to HIF-1α at HREs during hypoxia, suggesting a  
context-dependent function for LANA and a mechanistic explanation for hypoxia-driven reactivation [69]. 
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It remains unclear, however, how constitutively active HIF-1α is incapable of inducing Rta expression 
in the absence of hypoxia. X-box binding protein 1 (XBP-1), a critical inducer of the unfolded protein 
response (UPR) activated in stress conditions (including hypoxia) by the endoplasmic reticulum (ER) 
sensor BiP (Grp78), also directly transactivates Rta at ACGT-containing elements [91,92]. As  
XBP-1 activity induces B cell differentiation into secretory plasma-like cells, this process may be 
important for viral pathogenesis [91]. The aforementioned CBP, as well as p300, are transcriptional 
coactivators with intrinsic histone acetyltransferase (HAT) activity that bind to Rta at downstream Rta 
target promoters [7,37,52]. AP-1 is a complex of c-Jun and c-Fos proteins and may contribute the 
strongest transactivation activity for Rta expression, as evidenced by induction of a productive 
replication cycle by TPA that is similar to Rta-mediated induction [2,4,7,14,79,81,93]. Signal 
transducer and activator of transcription 3 (STAT3), a growth factor- and cytokine-responsive 
regulator, is dimerized by Rta, allowing STAT3 to translocate to the nucleus and induce STAT3 
transcriptional targets [94]. Rta also binds to C/EBP-α, and recruits basal transcription complex 
Mediator and chromatin remodeling complex SWI/SNF, at Rta promoters to potentiate viral gene 
transcription [4,7,37]. Oct1 is a cofactor with Rta, with binding sites in the Rta promoter stimulating 
Rta autoactivation, and conversely, in the LANA promoter to upregulate LANA as a negative feedback 
circuit [4,7,37,39]. Oct1 is also necessary for transactivation of the K-bZIP promoter [37,39]. K-bZIP 
itself can work cooperatively with Rta to facilitate transcription at select promoters, including for Rta, 
vIL-6, Mta and K-bZIP; as K-bZIP seems to both activate and repress its own promoter and have dual 
functions with Rta, its regulation of lytic replication is presumably complex [7,37].  
Finally, Mta, in addition to its functions described above, binds to and enhances Rta transactivation 
of selective downstream viral genes [37,50,55,95]. Loss or mutation of Mta showed that it is required 
for productive replication [37,50]. It is one of the first lytic genes expressed, one of the few directly 
targeted by Rta, and Mta protein can activate promoters in concert with Rta, including for itself, nut-1, 
Rta, kaposin and viral thymidine kinase (vTK) [37,50,81]. Mta also has transactivation potential alone 
in some contexts, as it can activate transcription of the nut-1 promoter independently of Rta; 
posttranscriptional roles likely exist for certain promoters as well, such as for nut-1 and viral DNA 
polymerase [37,50,95,96]. Mta binds mRNA and stabilizes a variety of transcripts, and one potential 
model is that Mta synergizes with Rta for transcriptional initiation and then enhances elongation by 
binding to and stabilizing nascent transcripts, where it may remain bound to enact its downstream 
activities [37,95,96]. Mta’s importance in productive replication was highlighted by data showing that, 
despite the aforementioned dearth of Rta-expressing cells positive for reactivation as indicated by K8.1 
expression (fewer than 20%), more than 80% of Mta-expressing cells were reactivated [37,50]. As Mta 
represents a much better predictor of virus proceeding through a complete lytic cascade, it has been 
characterized as a “commitment factor” that drives inefficient Rta function in the direction of 
productive replication [37,50].  
2.3. RBP-Jk Is Essential for Rta-Mediated Transactivation 
Of all single Rta cofactors, however, canonical Notch pathway effector RBP-Jk (also known as 
CSL, for EBV core promoter-binding factor [CBF]-1/suppressor of hairless [Su(H)]/longevity 
assurance gene [Lag]-1) is the only one shown to be essential for Rta transactivation activity at viral 
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and cellular promoters and for productive reactivation [4,7,37,47–49]. The Notch pathway is one of the 
oldest evolutionarily conserved signaling pathways in multicellular organisms [97]. It is involved 
primarily in development and cell fate, including intercellular communication and stem cell 
differentiation [97]. It also regulates apoptosis and angiogenesis, and Notch pathway dysregulation, 
which causes self-renewal and angiogenic tumor growth, is implicated in a variety of lymphoid 
cancers, such as T cell leukemias [97–100]. When signals including vascular endothelial growth factor 
(VEGF) and other cytokines induce Notch ligands Jagged or Delta-like to interact with one of the four 
human Notch single-pass transmembrane receptors, cleavage events release the Notch intracellular 
domain (NICD), which translocates to the nucleus and binds to RBP-Jk [46,97,98,100–104]. In the 
canonical Notch pathway, prior to NICD association, RBP-Jk is constitutively bound to promoter 
targets as part of HDAC corepressor complexes, at a (C/T)GTGGGAA consensus motif, and represses 
transcription [37,48,55,97]. NICD binding disrupts this repression, allowing it to recruit HAT proteins, 
signal through activated RBP-Jk and transcribe downstream Notch pathway genes, which include Hey 
and Hes family repressors [97,98,101,103,104].  
In KSHV-infected cells induced for lytic reactivation, Rta associates with RBP-Jk in order to 
transactivate downstream viral and cellular genes [37,46–49]. Many of Rta’s gene promoter targets are 
RBP-Jk-dependent (though many also require, or are enhanced by, additional interacting proteins, 
some of which were described above), including Mta, K-bZIP, LANA, vGPCR, IL-6, Hes1, vTK, 
modulator of immune recognition (MIR)1 and MIR2, vCCL1 and others [4,16,37,38,46]. In fact, 
RBP-Jk binding has been identified to at least 99 sites within the KSHV genome in infected cells 
( [105], and as many as 34 Rta transcriptionally-activated viral genes have been described; this 
suggests the potential for an Rta-RBP-Jk complex to induce the entire lytic cascade [37,106].  
Proof for RBP-Jk as a cofactor in Rta-mediated transactivation required for productive  
replication came in the form of truncation and mutation analyses of both proteins as well as target 
promoters [7,16,36,37,47–49,51,54]. The prototypical promoter for characterization of RBP-Jk 
interactions is Mta. RBP-Jk binding sites lie proximal to Rta binding elements [37,47,55]. Alterations 
to either of these sites reduced or prohibited Rta and/or RBP-Jk binding, transactivation or both, 
depending on location of a mutation within the promoter or on rearrangement between particular 
elements [37,47,55]. Independent binding of each protein at promoters, and subsequent ternary 
complex formation with promoter DNA, was required for optimal transactivation [37,47,53,55]. While 
RBP-Jk DNA binding was necessary for transactivation of Mta, RBP-Jk was found, unusually, not to 
constitutively bind to KSHV promoters in the absence of Rta, in sharp contrast to its mechanism for 
canonical Notch signaling [7,37,47–49]. This was determined by lack of RBP-Jk enrichment on viral 
promoters during latency, and by evidence that a constitutively active RBP-Jk mutant fused to the 
TAD of HSV-1 protein VP16 (RBP-Jk/VP16) was unable to bind to promoters alone [37,47,49]. Rta 
DNA binding, meanwhile, was determined to not be sufficient for transactivation at some  
RBP-Jk-dependent promoters [37,47,51]. An Rta mutant lacking its TAD, which begins at aa 530, but 
with its DBD (aa 1-272) intact (RtaΔSTAD), was also unable to activate its downstream genes alone; 
however, when combined with RBP-Jk/VP16, RtaSTAD rescued RBP-Jk DNA-binding at the Mta 
promoter [37,47]. The interaction also rescued transactivation [37,47]. Meanwhile, RBP-Jk-null 
fibroblasts were deficient in transactivation at Mta, but not nut-1, which is a direct Rta target; ectopic 
expression of RBP-Jk rescued this activity [37,48,49]. Taken together, Rta binding to RBP-Jk appears 
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to stimulate RBP-Jk DNA binding at Rta downstream promoters containing both Rta- and  
RBP-Jk-specific elements, and in conjunction with additional cofactors at certain promoters, activates 
gene transcription.  
While this basic model for RBP-Jk-dependent, Rta-mediated transactivation addressed many of the 
questions surrounding regulation of KSHV gene expression, it was still not fully understood how Rta 
physically bound to its promoter elements in complex with RBP-Jk. Originally, 40 nt and 26 nt sequences 
containing identical, 16-nt palindromic RREs were defined within the Mta and K-bZIP promoters adjacent 
to an RBP-Jk binding site, but as flanking mutations in the Mta promoter, including in TATA-proximal 
sequences, revealed profound defects to transactivation without affecting RBP-Jk binding, the architecture 
required for Rta binding developed into a more complex picture [7,37,46–48,55]. First, it was noted that 
Rta elements were present upstream and downstream of the RBP-Jk binding site [7,37,46–48,55]. Second, 
Rta bound with high affinity to A/T trinucleotide repeat units within these elements, and the number and 
position of elements corresponded to the strength of Rta DNA binding [7,37,46–48,55]. Third, DNA 
footprinting mapped to four sites, distal and proximal to the RBP-Jk element, with the proximal sites 
flanking both sides of the element [37,55]. These four sites overlapped with A/T repeats. It was 
determined that the sites shared the consensus sequence ANTGTAACANT(A/T)(A/T)T, known as the 
“CANT DNA repeat” [37,55]. These units were repeated seven times in the four sites, two of which 
formed palindromes [37,55]. Further, it was shown that CANT repeats are present at a variety of Rta 
responsive promoters adjacent to RBP-Jk binding motifs (including at oriLyts), and represent a 
broadly-applicable RRE that defines Rta-RBP-Jk ternary complex formation and transcriptional 
mechanics [37,46,55]. Rta binds relatively weakly to single CANT DNA elements or palindromes, but 
binds with nM affinity to the full cohort of 7 CANT repeats in the Mta promoter. 
Rta is not alone in its ability to mimic the NICD and use RBP-Jk for KSHV’s own pathogenesis. 
Epstein-Barr virus nuclear antigen (EBNA) 2 also binds to RBP-Jk to transactivate EBV downstream 
genes in a manner analogous to NICD [2,4,7,34,37,41,46,103,104]. However, EBNA2 utilizes  
RBP-Jk by different means. For instance, RBP-Jk is required for EBNA2-mediated establishment and 
maintenance of latency, and their interaction depends solely on NICD-like binding to RBP-Jk’s  
beta-trefoil domain (BTD), which blocks the activity of the larger RBP-Jk central repression domain 
(CRD) [37,47,49,107]. This interaction is defined by the conserved RBP-Jk binding peptide signature 
GPPWWPP, shared by both EBNA2 and NICD [37,47,49,107]. Finally, neither EBNA2 nor NICD can 
optimally transactivate KSHV genes with RBP-Jk alone, save a few exceptions, and cannot induce 
KSHV lytic reactivation [37,47,49,107]. Rta, conversely, requires RBP-Jk for lytic reactivation;  
can bind to RBP-Jk’s BTD, as well as N-terminal domains; can recruit RBP-Jk to EBV promoters  
and upregulate latent genes; and, importantly, does not contain the seven-nt consensus binding  
peptide for its interaction with RBP-Jk, instead relying on a currently unknown, noncanonical  
motif [4,34,37,41,46–49,107].  
While the motif itself still needs to be elucidated, it is clear based on functional binding studies that 
Rta interaction with RBP-Jk occurs within a 117 aa region of Rta between aa 414 and 530, just  
N-terminal to the Ser/Thr-rich domain and inclusive of the NLS [37,47]. This was further determined 
by transactivation analysis, in addition to direct RBP-Jk binding studies, in which RtaSTAD was 
further truncated to Rta aa 414 [37,47]. This Rta mutant, unlike RtaSTAD, was unable to rescue 
transactivation of the Mta promoter with RBP-Jk/VP16, nor was it able to form ternary complexes 
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with RBP-Jk and promoter DNA in supershift assays [37,47]. Thus, these data suggested that the 
minimal Rta region required for binding RBP-Jk was aa 414–530; this domain functions in concert 
with Rta’s DNA binding domain to stimulate RBP-Jk DNA binding to Rta responsive promoters. 
Nevertheless, the requirement for this domain is in contrast to an N-terminal region in Rta, between aa 
170 and 400, which was shown to bind to RBP-Jk in solution, but was not sufficient alone for ternary 
complex formation and transactivation [37,47,48]. Taken together, the aa 414–530 region of Rta is 
required for both binding by RBP-Jk and stimulation of transactivation-competent ternary complex 
formation with promoter DNA.  
Finally, in a study from our lab that bridged Rta CANT repeat recognition with its physical 
interaction with RBP-Jk at downstream promoters, it was revealed that RtaSTAD inhibited 
Rta-mediated transactivation and lytic replication, suggesting that RtaSTAD acted as a DN against 
WT Rta [35]. Thus Rta formation of mixed multimers was a required for its function. Further analysis 
showed that of all multimers, tetramers were sufficient to mediate the ability of Rta to transactivate 
genes [37,54]. Functional binding studies mapped the minimal tetramerization domain of Rta to aa 244 
to 414 [37,54]. This region was notable for its inclusion of a 31 nt, N-terminal leucine heptapeptide 
repeat domain (LR) [37,54]. The KSHV Rta LR is similar to leucine zippers (LZs) in yeast, and shares 
a similar structure to Rta homologs in other primates, including three conserved leucines spaced at 
seven-residue intervals [37,54]. LZs are known to form alpha helix-based coiled coils and play a role 
in protein dimerization [37,54,108,109]. However, the KSHV Rta LR is also divergent from LZs in 
that it contains a high proline content; the LR overlaps with Rta’s proline-rich region [37,54,108,109]. 
The five prolines within the LR are conserved among γ-herpesvirinae, and had originally been predicted 
to prevent coiled coil formation typically important for canonical LZ oligomerization [37,40,54,108,109]. 
As the KSHV Rta LR was necessary for tetramer formation, it was hypothesized that the region might 
enable this function without a need for the hypothetical coiled coil structure [37,54]. To ensure coiled 
coils weren’t required for higher order Rta, the conserved leucines were mutated to prolines. The  
Rta-L3P mutant formed almost exclusively tetramers, confirming the nonessentiality for a typical LR 
structure in this activity [37,54]. Surprisingly, Rta-L3P was capable of WT levels of transactivation and 
reactivation [37,54]. It was concluded that Rta tetramers are essential for its transactivation potential 
and that, interestingly, the proline content within and beyond the LR, but not the LR’s canonical 
secondary structures, may be important in determining Rta’s higher order status—and perhaps broader, 
additional functions—based on their modification [37,54].  
Given the body of evidence, a dynamic model for Rta transactivational function has been proposed: 
Rta protein forms tetramers and binds to RREs in viral and cellular promoters, alone or in conjunction 
with essential cofactors; straddling of Rta tetramers that contact multiple, flanking palindromic CANT 
DNA repeats, via binding of a novel Rta peptide motif to RBP-Jk, targets RBP-Jk to its element 
present in many Rta gene targets, allowing for the recruitment of additional coactivators and initiation 
of gene transcription [37,46,47,54,55]. Success of this transactivation program is critical to completion 
of the entire lytic cycle cascade, and relies on the interplay between Rta’s interaction with cofactors 
and, likely, on guidance by putative, proline-directed modifications that regulate Rta to carefully 
define its activities throughout viral reactivation [2,4,7,37,42,46,49]. It is the recent report published 
by our lab describing one such putative proline-directed modification of Rta—regulation by proline 
isomerization—that is the major focus of this review.  
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3. Function, Regulation and Dysregulation of Pin1 Isomerase and its Novel Role in KSHV  
Lytic Reactivation 
Posttranslational modifications are absolutely vital to the proper function of proteins within a cell, 
for signaling, conformation, interactions with other factors, stability, localization, DNA binding and 
transactivation, among many others. A number of potential modifications to Rta include 
phosphorylation, sumoylation, ubiquitylation and proline-directed modifications such as prolyl 
hydroxylation and prolyl isomerization [2,4,7,34,37,42–46,54,55,64,68,110]. The demonstrated 
importance of prolines within Rta may not have been limited to a role in tetramerization, but could 
have broader consequences on Rta function.  
Such modification is possible by peptidyl-prolyl cis/trans isomerases (PPIases) [111]. 
Isomerization of proline was first discovered as an important mechanism for proper protein function 
in the context of nascent protein folding [111–115]. The ability of primary amino acid structure to 
correctly fold into a functional conformation following ribosomal synthesis within the ER is largely 
dictated by the physical properties of the amino acids themselves. As trans form residues are solely 
synthesized by ribosomes, any protein that requires cis form residues would be unable to correctly 
fold and function. However, proline isomerization, by itself, is a rate-limiting process occurring at 
the multi-minute timescale [115–117]. A cell would be unable to survive if its protein contents took 
so long to mature.  
Peptidyl-prolyl cis/trans isomerases (PPIases) are highly conserved cellular catalysts that bind to 
and isomerize prolines at millisecond timescales, thus, effectively allowing for rapid, 
physiologically-relevant protein folding and function [111,113,115,116]. They are found in all 
organisms, including bacteria. There are four classes of PPIases: cyclophilins (Cyps), FK506-
binding proteins (FKBPs), parvulins and the protein Ser/Thr phosphatase 2A (PP2A) activator 
(PTPA) [111,113,115,116]. The initial characterization of Cyps and FKBPs revealed them as targets 
for immunosuppressive and anticancer drugs cyclosporine A, FK506 and rapamycin, though it was 
soon reported that this was unrelated to their PPIase activity [111,113,114,116]. Further, their 
biological significances were questioned due to their redundancy, the presence of dedicated 
chaperone molecules and that disruption of single or multiple PPIase genes did not affect cell 
viability [111,114,118]. It did not appear that PPIases were essential general factors, although in 
subsequent years, important specific interactions were described. For FKBPs, for instance, FKBP12 
was found to associate with ryanodine and inositol 1,4,5-triphosphate (IP3) receptor subunits and 
inhibit TGF-β receptors [111,113–115,119]. Interestingly, cyclophilins appear to be important in the 
pathogenesis of various virus, including HIV-1, hepatitis C virus (HCV) and human cytomegalovirus 
(HCMV, human herpesvirus 5) [111,113–115,120]. 
3.1. Human PPIase and Cell Cycle Regulator Pin1 
In 1996, a new class of PPIases, parvulins, was identified as the result of a screen in  
Aspergillus nidulans for direct binding inhibitors of the essential mitotic kinase never in mitosis A 
(NIMA) [116,121,122]. The screen isolated three human proteins, one of which was peptidyl-prolyl 
isomerase NIMA interacting protein (Pin)1, a small 18 kDa protein determined to be a novel PPIase 
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containing characteristic N-terminal WW substrate binding and C-terminal PPIase catalytic domains 
(Figure 2) [121,123–125]. Despite sharing the same basic domains with similar enzymatic activity, 
Pin1 was found to have a dramatically different structure from the other PPIase classes (which 
themselves are structurally distinct) [111,115,123,126].  
 
 
Figure 2. Pin1 prolyl isomerase protein structure. Secondary amino acid (a) and  
Space-filling (b) models show Pin1, a small, ~18 kDa protein consisting of two domains: a 
WW binding domain (purple) named after two invariant tryptophans, and a peptidyl-prolyl 
isomerase (PPIase) domain (blue) that catalyses cis-to-trans isomerization. The WW 
recognition motif is visualized by the RNA polymerase (RNAP) II carboxyl terminal 
domain (CTD) peptide, which, unique to cellular isomerases, is a phosphorylated serine or 
threonine directly N-terminal to a proline (pS/T-P motif). This motif is also acted upon by 
the catalytic binding pocket of the PPIase domain. The two domains are connected via a 
flexible loop linker (at top) in the PPIase domain that allows for inter-domain coordination. 
Figure reproduced with permission from Lu and Zhou, Nature Reviews Molecular and 
Cellular Biology; published by Nature Publishing Group, 2007 [127].  
Pin1 showed conservation from yeast (where it is known as Ess1) to humans 
[111,115,116,121,123,128]. Its role as a suppressor of NIMA-induced mitotic catastrophe marked the 
first non-“housekeeping” function ascribed to isomerases, in that it was both essential for cell viability 
in general, and as a regulator of mitosis specifically [121]. Additional characterization of Pin1 showed 
an intriguing specificity for peptidyl-prolyl motifs that required phosphorylation of the N-terminal 
peptidyl residue for recognition and for isomerization [115,116,123,129]. Peptidyl residues must be, in 
the case of Pin1, phosphoserines or phosphothreonines. It appeared that Pin1 WW domains bound to pS-P 
or pT-P (known as “pS/T-P motifs”) in targets by recognition of the phosphorylation, which reduced the 
double-bonded character of the oxygen N-terminal to the peptide bond (Figure 3A) [115,116,123,126,130]. 
As for all PPIases, this significantly reduced the torsion barrier that restricted rotation about the 
peptide bond from trans to cis forms (or vice versa), rapidly speeding up the conversation rate by 
several orders of magnitude [111,115,116,126]. 
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Figure 3. Mechanism of prolyl isomerization and its effect on substrate function. 
(A) Cis-trans isomerization is an intrinsically slow process; PPIase catalysis at pS/T-P 
motifs reduces this timescale from minutes to milliseconds, by binding to the phospho-
residue N-terminal to proline, which the double-bonded oxygen and thus, the torsion 
barrier preventing conversion, allowing for a 180° rotation about the bond. (B) Since 
only trans-form of prolines bcan e acted on by regulators, isomerization can “lock” 
phosphorylation, and therefore a substrate’s function (such as, for example, stability of 
the human T cell leukemia virus (HTLV)-1 Tax oncoprotein, above), in place. As such, 
Pin1 is regarded as a timer of a variety of critical cell cycle and signaling events, 
including for those involving both cellular and viral regulators. Figure reproduced with 
permission from Lu et al., Nature Chemical Biology; published by Nature Publishing 
Group, 2007 [115], and from [131].  
The findings pertaining to Pin1’s phosphorylation dependency were significant for a few reasons. 
First, phosphorylation greatly slows the spontaneous cis-to-trans conversion rate and makes catalyzed, 
reversible isomerization essential for proteins requiring a particular conformation for function [115]. 
Second, no other PPIase recognized motifs that contained phosphorylated residues [111,115,123]. Third, 
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and most importantly, action at phosphorylated moieties strongly implied that Pin1 has broadly-applicable 
regulatory potential at a previously unrecognized, postphosphorylational level [115,130,132,133]. This 
is because kinases and phosphatases are involved in numerous cell signaling events and are capable of 
targeting trans form serines and threonines only [115]. Thus, Pin1 binding to specific motifs within 
important regulatory or effector proteins render phosphorylation (or lack thereof) “locked in” by a 
switch to cis form, resistant to kinase or phosphatase activity. Protracted “on” or “off” states under the 
control of Pin1 isomerization, then, alter protein function and subsequently the conduct of their 
constituent pathways (Figure 3B). 
3.2. Dysfunction of Pin1 Is Often Associated with Tumorigenesis 
It was quickly borne out that Pin1 was indeed an integral cell-signaling regulator [115,121,123,130]. 
Perhaps its best-studied, and most important single interaction lies with Cyclin D and the G1/S 
checkpoint, a prime example of Pin1’s postphosphorylational control [115,119,130,133–136]. Pin1’s 
role, however, extends beyond cell cycle signaling; it is a truly pleiotropic enzyme with a wide array of 
substrates (Table 1). 
Under normal conditions in noncancerous tumors, evidence suggests that Pin1 acts in a general tumor 
suppressive capacity [115,121,128,130,132,133,137–141]. Overexpression of Pin1, however, is attributed 
to a large number of malignancies at both the tumor and molecular levels [119,127,133–135,142–148]. 
Pin1 has been implicated in colorectal cancer (β-catenin), breast cancer (Cyclin D, AP-1, Akt, 
centrosome duplication, Notch1), prostate cancer (TRK-fused gene [TFG]), glioblastoma (NF-κB), 
hepatocellular carcinoma (HCC, p70S6K, β-catenin) and acute myeloid leukemia (AML, AP-1) 
[134,135,142–145,147–152]. The particular Pin1-dysregulated substrates and pathways are not mutually 
exclusive, and many of them are affected in cell type- and tumor type-specific combinations. 
Importantly, in a comprehensive study of over 2000 human tumors representing 60 types of cancer, Pin1 
was found to be at least 10% overexpressed in 38 of the 60 tumor types, especially for breast, colon and 
prostate cancers [135]. In support of this, a clinical study of nearly 600 prostate cancer patients, Pin1 was 
strongly associated with cancer severity and recurrence risk [153].  
Finally, Pin1 was also more recently implicated in virally-derived tumors as well as in viral 
pathogenesis in general. For instance, HIV-1 capsid (CA) protein uncoating, a process essential for 
subsequent reverse transcription and viral replication, is mediated by Pin1 activity [154,155]. So 
too does Pin1 interact with and inhibit APOBEC3G, a cytidine deaminase and antiviral factor that 
incorporates into HIV-1 virions to block viral replication, as well as stabilizes the HIV-1 integrase 
for incorporation of virus into host genomes [156]. Pin1 promotes ubiquitylation of IRF3, 
inhibiting the host IFN innate antiviral response and promoting susceptibility to viral infection  
[157]. For hepatitis C virus, Pin1 interacts with viral nonstructural proteins NS5A and NS5B to 
enhance HCV replication [158]. Hepatitis B virus (HBV) encoded protein X (HBx) stability is 
mediated by Pin1, which is associated with HCC [159]. Notably, Pin1 stabilizes the human T cell 
leukemia virus 1 (HTLV-1) oncoprotein Tax, a transcription factor similar to KSHV Rta, at least 
thematically, in that it transactivates downstream viral promoters for productive lytic replication 
and pathogenesis [131,133,160,161]. Stabilization allows Tax to interact with IKKγ and contribute 
to NF-κB-mediated cell transformation [161]. 
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Table 1. Prominent Pin1 isomerization substrates and functional effects. 
Substrate Substrate Type Pin1 Interaction Proposed Pin1 Function 
Akt 
p70S6K 
PI3K pathway kinase Stabilizes/activates  Oncogenic dysregulation of downstream metabolic, proliferative, antiapoptotic pathway functions 
Cyclin D 
pRb 
G1/S activator 
G1/S inhibitor 
Stabilizes/relocalizes 
Deactivates 
 Increases checkpoint activation and cell cycle progression 
Pim1 Oncogenic kinase Destabilizes  Blocks Pim1 antiapoptotic, cell cycle signaling, differentiation activity 
Raf1 
RSK2 
MAPK pathway kinases 
+ Dephosphor/stabilizes 
+ Phosphor/stabilizes 
 Enhances AP-1 mediated transcription of Cyclin D 
SMAD Transactivator Reduces protein levels  Blocks TGF-β signaling 
Cdc25 
Incenp 
NIMA 
Survivin 
TopoIIα 
Wee1 
Mitotic regulators 
Promotes dephosphor 
Unknown interaction 
Decreases activity 
Decreases protein levels 
Promotes phosphor 
Deactivates 
 Regulates kinetics of mitosis progression and completion 
Centrosome Organelle Enhances activity  Promotes centrosome duplication prior to mitosis 
Histone H1 Chromatin binding protein + Dephosphor/enhances binding  Promotes chromatin binding, condensation, transcriptional repression 
Actin 
Tau 
Cytoskeletal proteins 
Unknown interaction 
Promotes dephosphor 
 Unknown function (actin); bound and incorporated into HIV-1 virions 
 Limits abnormal microtubule/tangle formation, tauopathies (tau) 
KRMP1 Kinesin-like motor Unknown interaction  Putative mitotic regulator and/or mitotic substrate transporter 
c-Myc TF Enhances activity/destabilizes  Promotes selective activation of cell proliferative/metabolic genes 
HDAC3 Deacetylase Destabilizes  Promotes oncogenic transcriptional activation 
SMRT Transcriptional repressor Destabilizes  Blocks recruitment of HDACs to promoters, promotes transcription 
β-catenin TF Stabilizes/activates  Blocks repression, allowing Cyclin D upregulation 
Bcl2 Antiapoptotic regulator Destabilizes/deactivates  Prevents inhibition of apoptosis 
c-Jun/c-Fos TFs Stabilizes/activates  Activates transcription through MAPK-AP-1 pathway 
p53 DNA damage response TF Stabilizes/activates  Promotes apoptosis and cell cycle arrest 
p65 (NF-κB) TF Relocalizes/stabilizes  Prevents inhibition, activates angiogenic, antiapoptotic genes 
Notch1/NICD Growth factor receptor Stimulates cleavage  Promotes NICD release, downstream Notch signaling with RBP-Jk 
Hif-1 
BiP/Grp78 
Hypoxia regulator  
ER stress regulator 
Upregulates expression  Enhances HIF-1-mediated VEGF production, UPR activation 
APP Membrane protein + Dephosphor/destabilizes  Prevents improper processing, accumulation of amyloid-β plaques 
ADAR2 Adenosine deaminase Stabilizes  Promotes editing of GluR2 mRNA for calcium flux in neurons 
Nanog 
Oct4 
Self-renewal TFs Stabilizes/enhances activity  Represses differentiation of embryonic stem cells 
RNAP II CTD 
hSpt5 
Transcriptional regulators Controls activity/relocalizes  Regulates transcription termination, elongation, RNA processing, RNAP II storage 
TRF1 Shelterin member Destabilizes  Prevents shortening of telomeres, telomere dysfunction 
APOBEC3G 
Capsid protein 
Integrase 
Cytidine deaminase 
HIV-1 virion protein 
HIV-1 enzyme 
Inhibits activity 
Stabilizes 
Stabilizes 
 Blocks HIV-1 restriction, promoting replication 
 Promotes capsid uncoating 
 Promotes HIV-1 incorporation into the host genome 
BALF5 EBV polymerase catalytic subunit Enhances activity  Enhances viral replication 
Hbx HBV transactivator Stabilizes  Enhances HBV-induced hepatocarcinogenesis via signaling dysregulation 
IRF3 IFN response regulator Destabilizes homodimers  Represses IFN innate antiviral response 
Tax HTLV-1 transactivator Stabilizes/activates  Enhances transcriptional activity and oncogenesis 
+ (De)phosphor = promotes (de)phosphorylation. Abbreviations and citations in text.  
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3.3. Pin1 Has a Novel Role in KSHV Lytic Reactivation 
Pin1 has been found to play a role in herpesviral pathogenesis as well. In HCMV infection, Pin1 is 
recruited to aid reorganize nuclear lamin A/C upon phosphorylation of the lamina by viral kinase 
pUL97 and cellular PKC [162]. Pin1 also associates with a number of proteins that could play roles in 
viral egress, including microtubule binding protein tau, actin filaments (which are known to be 
incorporated into virions during assembly) and, interestingly, kinesin-related protein KRMP1, a motor 
protein similar to kinesin or myosin that may play an important role, together with Pin1, in regulation of 
mitosis, potentially through the transport of Pin1 and other mitotic substrates [119,133,163,164]. And in 
a recent study by Narita et al., Pin1 was found to bind to γ-herpesvirus EBV protein BALF5, the 
catalytic subunit of the viral DNA polymerase, and enhance EBV replication [165].  
Recently, our lab investigated a putative interaction between KSHV Rta and PPIase Pin1 in the 
regulation of Rta-mediated lytic reactivation at multiple stages of the lytic cycle cascade. In silico 
alignment analysis of the transcription activation factor (TAF) 50 superfamily revealed that Rta 
homologs share a consensus of 134 amino acids (residues conserved between KSHV Rta and at least 
one additional member). Proline consists of 38 of these amino acids, accounting for 16.7% of all of 
Rta’s conserved residues (Figure 4) [40,166]. The high degree of conservation supported their putative 
functional significance. We reasoned that modification of prolines may regulate Rta’s efficiency in 
transactivating target genes, licensing viral DNA replication and interacting with protein partners—which 
could drive the latency-lytic cycle balance in favor of productive replication.  
In our report, we demonstrated an interaction between cellular isomerase Pin1 and KSHV lytic 
switch Rta. We showed that Pin1 is expressed and active in infected PEL cells after lytic cycle 
induction, and that Pin1 directly interacts with Rta in vitro and in infected cells, most likely at one of 
Rta’s putative conserved Pin1-recognition (pS/T-P) motifs [166]. Pin1 did not, however, interact with 
the essential Rta cofactor and Notch effector RBP-Jk by GST pulldown assay [166]. Pin1 enhanced 
Rta transactivation at two viral promoters in transient transfections [166]. Cotransfection of  
Rta with Pin1 appeared to result in enhanced redistribution of Rta from punctae to strong pan-nuclear 
expression in the majority of cells that coexpressed Pin1 (89%) [166]. This effect seemed to involve 
minute amounts of Pin1, as most coexpressed cells with Pin1 even modestly over background displayed 
Rta relocalization [166]. Overall Rta expression was also markedly stronger between punctae and  
pan-nuclear localization. In WT and Rta-inducible, virally-infected PEL, iSLK and Vero cells, we 
showed that Pin1 has a time-dependent effect on lytic reactivation, enhancing early-stage but inhibiting 
late-stage lytic cycle function [166]. Early-stage enhancement was shown via Rta-mediated DE 
transactivation and viral DNA-based experiments that overexpress or ablate Pin1. Late-stage inhibition 
by Pin1, meanwhile, was shown via reactivation experiments in WT and Rta-inducible PELs, in a  
Rta-inducible iSLK BAC16-based cell line system in which the viral allele of Rta is rendered defective by 
insertion of a stop codon (BAC16-RTAstop), and finally in a new, two-step KSHV reporter Vero-based 
cell line system developed by Gantt and colleagues that contain the secreted alkaline phosphatase 
(SeAP) gene under the control of an upstream tetracycline responsive element (TRE) promoter [167]. 
Together, those studies suggest that expression of late gene K8.1, and subsequent infectious virion 
release, are markedly inhibited [166,168]. 
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Figure 4. Rta protein is rich with conserved prolines. 17% of Rta’s conserved aa are prolines. At bottom are Rta primary sequence alignments 
of two proline-rich regions (A) and (B), denoted by yellow and green boxes, to the TAF50 γ-herpesvirinae superfamily. Numbers indicate aa 
position. +++ = positively-charged aa-rich, LR = leucine heptapeptide repeat domain, S/T = serine/threonine-rich, hyd DE hyd = 
hydrophobic/charged/hydrophobic aa-rich, NLS = nuclear localization signal sequence. Red lines mark putative phosphorylated residue sites;  
* = known phosphorylated residue. Figure modified from [166]. 
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Our published report showed that KSHV co-opts Pin1 function as a molecular timer, where by Pin1 
enhances Rta expression, Rta transactivation activity at Rta-responsive promoters and Rta-mediated 
viral DNA replication, but inhibits late gene synthesis and virion production [166]. We propose that 
this dichotomy of Pin1 function can impart KSHV with a prosurvival, abortive lytic reactivation 
pathway, one which we hypothesize may regulate viral pathogenesis through the expression and 
activity of lytic cycle oncoproteins. To our knowledge, we mark the first discovery of an interaction 
between a DNA virus transcription factor and Pin1. 
4. Significance of Convergence of Pin1 Function with Regulation of KSHV Lytic Reactivation 
4.1. Ectopic Pin1 Is Sufficient to Induce Rta Expression: Putative Mechanisms 
Early Pin1 activity may be important due to its sufficiency to induce Rta expression. Pin1 is known 
to affect protein expression in a number of ways. First, it could upregulate Rta transcription through well-
described signaling pathways. Chief among them are c-Jun and c-Fos, which constitute the transcriptional 
regulator activating protein (AP)-1, as well as hypoxia inducible factor 1α (HIF-1α, an important regulator 
within the hypoxia response [89,92,169,170]. In PEL cells, HIF-1α is always active due to LANA inhibition 
of VHL [171]. HIF-1α can then activate Rta expression as well as Rta co-activators [69,89,90,172]. It is 
intriguing that Pin1 engages in a positive feedback mechanism with HIF-1α during the hypoxia  
response [146,147,173]. Additionally notable is that the ER stress response sensor BiP is upregulated by 
Pin1, an activity that is conserved with other PPIases in their role as protein folding regulators [174]. 
Meanwhile, AP-1 involvement in potential Pin1-dependent Rta transactivation has additional implications. 
Pin1 function upstream of Rta IE gene expression, and through the AP-1 pathway, is highly similar to 
TPA’s mechanism of lytic induction [81,134,151,152,175]. In Pin1 −/− MEFs, TPA induction of the AP-1 
pathway was found to be much weaker than in Pin1 +/+ MEFs [175]. Second, Pin1 could affect 
transcriptional elongation and posttranscriptional splicing [115,128,137,176]. This could occur via 
Pin1's described interaction with RNA polymerase (RNAP) II [137,176,177]. Pin1 has been shown to 
play a role in control of carboxyl-terminal domain (CTD) phosphorylation [177]. The combination of 
phosphorylation and cis/trans isomerization designates the so-called “CTD code” that coordinates 
proteins involved in RNAP II-mediated events, including mRNA processing [128,177]. Future studies 
of Rta transcriptional and posttranscriptional control in the presence of Pin1, as well as Pin1 promoter 
binding and activity studies in infected PELs, will help confirm and define the above-suggested interplays. 
4.2. Pin1 Directly Binds to Rta and Enhances Rta Transactivation 
In our report, we found that Pin1 and Rta directly interact in vitro and in infected cell lysates.  
As with most of its protein substrates, Pin1 could enhance expression independently of its 
transcriptional effects through direct stabilization of Rta protein. Pin1 often stabilizes proteins that may 
otherwise be ubiquitylated and targeted for proteosomal degradation, such as Cyclin D [115,133,178]. 
The most applicable examples of this are the viral Tax and HBx oncoproteins and transcription factors 
of HTLV-1 and hepatitis B virus (HBV), respectively, as previously discussed [159,161]. These factors 
are prevented from degradation by conformational changes induced due to prolyl isomerization, allowing 
their protein levels to accumulate for efficient downstream activities, including transactivation and 
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productive viral replication. It is possible that Pin1 could affect Rta stability by either inhibiting Rta 
auto-ubiquitylation via Rta’s E3 ubiquitin ligase domain, or by enhancing Rta-induced degradation, 
also through its E3 ligase activity, of Rta repressors such as K-RBP and IRF7 [63,64,68]. Indeed, these 
repressors bind to Rta within proline-rich regions containing putative Pin1 isomerization motifs; Pin1 
activity could prevent their association. 
As we observed that the Pin1 interaction appeared to be stronger with full-length WT Rta, we cannot 
rule out that Pin1 has multiple binding motifs within Rta. First, Pin1 is known to bind to a number of 
its targets at more than one motif; this includes p53, c-Jun, Nanog and Akt [126,133,134,178–180]. 
Second, Pin1 binding and isomerization activities are separable and complex. Binding motifs can be 
recognized by each domain and acted upon with different specificities [111,115,116,123,130,181]. In 
other words, Pin1 can bind one motif, but very well isomerize another. 
Other possible motifs could also have binding and/or isomerization specificity, including Thr449, 
Thr515, Ser634 (which is a fully conserved Pin1 motif) and Ser636 (Figure 5) [166]. The latter three, 
in this case, are interesting putative motifs, as they are the only known potential Pin1 sites to date that 
has been previously shown to be phosphorylated in in vitro binding assays or in infected cell-based 
Western blots, by Rta transactivation inhibitor hKFC (for Thr515) and CDK9 (Ser634/636), 
respectively (and it bears mentioning that the other, putative CDK binding sites, at Thr449, Thr540, 
Thr628, Ser644 and Ser650, are also all putative Pin1 sites) [42,44,45]. CDK9 kinase activity on Rta is 
notable because CDK9 is a catalytic subunit of positive transcription elongation factor b (P-TEFb), 
which associates with the promoter-paused RNAP II’s CTD and activates transcriptional 
elongation [44]. Rta likely recruits CDK9 to viral promoters, where the kinase licenses transcription as 
well as positively regulates Rta activity. Pin1, which as previously discussed, binds to the CTD and 
regulates transcriptional elongation, is known to bind to CDK9-phosphorylated substrate hSpt5, an 
elongation inhibitor [137,182]. Thus, Pin1 interactions with both CDK9 targets, hSpt5 and Rta, could 
enhance RNAP II transcriptional elongation at KSHV gene promoters. While it is tempting to suggest 
that these could represent bona fide pS/T-P motifs, the cytosolic localization of hKFC makes an 
Rta-regulating Pin1 modification through hKFC in infected cells suspect, while for CDK9, in light of 
the lack of Pin1 binding to the Rta aa 525–691 truncation mutant, a true Pin1 motif beyond aa 525 
appears less likely [45,166]. Nevertheless, Pin1 binding at Ser634/636 in infected cells, alone or 
combined, could still be possible, and future functional binding analysis with Pin1 motif mutants of 
Rta will be required to clarify this interaction. Taking into account the intricate regulation by Pin1 
reported throughout this review, multiple binding sites could provide Pin1 with a combinatorial 
influence on Rta function, much as Pin1 coordinates the CTD code of RNAP II, based directly on the 
phosphorylation status of certain motifs. This control could be one explanation for the divergent effects 
of Pin1 during the lytic cycle, which will be further addressed below. 
Pin1 binding to Rta could mediate a variety of different effects on Rta beyond stability, including 
tetramerization. Bearing in mind the importance of conserved prolines on Rta higher-order structure, 
that Pin1 binding to the Rta aa 170–400 region overlaps with the tetramerization and proline-rich 
domains (Figure 1), the putative Pin1 motif at Thr388 (Figure 5) and that previous data showed that 
RBP-Jk also binds to Rta aa 170–400 in solution [47,48], it is reasonable to suggest that Pin1 binding 
to Rta could regulate Rta’s tetramer formation, allowing it to interact with RBP-Jk and transactivate 
downstream viral and cellular genes [166]. 
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Figure 5. Rta protein has putative, conserved Pin1 motifs. Blue bars indicate 15 putative 
S/T-P motifs, sites for Pin1 binding and isomerization, which are characterized by a 
phosphoserine or phosphothreonine immediately preceding a proline. Letters indicate aa 
that are parts of possible Pin1 motifs that are phylogenetically conserved between KSHV 
Rta and at least one additional γ-herpesvirinae family member ORF50 homolog (part of 
the TAF50 protein superfamily). Motif bars colored in red indicate those that are known to 
be phosphorylated (T515, S634 and S636; see Figure 4). Putative Pin1 motifs T449, T540, 
T628, S644 and S650 are also putative phosphorylated residues. Boxes at bottom show 
alignments of proline-rich and RBP-JK binding regions of Rta. Numbers indicate aa 
position. +++ = positively-charged aa-rich, LR = leucine heptapeptide repeat domain, S/T 
= serine/threonine-rich, hyd DE hyd = hydrophobic/charged/hydrophobic aa-rich, 
NLS = nuclear localization signal sequence, P = conserved proline, S = conserved serine, 
T = conserved threonine, M = fully conserved S/T-P motif. Figure modified from [166]. 
In the literature, Pin1 has been previously reported to affect protein multimerization, in that case 
destabilizing IRF3 homodimer formation [157]. Pin1 also has a known role in upregulating Notch1 
activity through enhanced cleavage of NICD by γ-secretase, which it could perhaps do in KSHV-infected 
cells in concert with the reported stabilization of NICD by LANA or activation of Notch4 by 
vGPCR [101,147,183]. NICD can weakly bind to RBP-Jk alone for modest transactivation at viral 
promoters, but can act synergistically with RtaΔSTAD due to the effect of NICD’s transactivation 
domain [47]. 
It is important to point out that, although we tested and confirmed that Pin1 greatly enhanced  
Rta-mediated transactivation and DE gene expression using well-studied promoter markers nut-1 and 
Mta, we did not directly observe Pin1’s effect on KSHV’s lytic cycle oncoproteins, such as vGPCR or 
vIL-6, etc. Therefore, while our data suggest that Pin1 affects DE gene expression nonspecifically, we 
cannot make concrete conclusions. The same is true in regards to Pin1’s effect on KSHV oncogenic 
properties, including VEGF production and angiogenesis, cell cycle disruption and apoptotic 
subversion. Could Pin1 expression and/or activity distinguish Rta-initiated reactivation cascades that 
differ in expression of replication protein from oncoproteins? If so, could Pin1 activity determine the 
oncogenicity of KSHV infection? As the purpose of our investigation was to identify and characterize 
the qualitative role of Pin1 on the Rta lytic switch and on lytic reactivation, further studies addressing 
such questions will develop Pin1’s lytic cycle-based molecular mechanisms as well as the broader 
phenotypic and tumorigenic ramifications of these, and other, activities at multiple stages of the KSHV 
life cycle, including in de novo infection and egress. 
The mechanism of how, exactly, Pin1 strengthens Rta-mediated transactivation and DE gene 
expression is unclear and the subject of ongoing examination. Additional, indirect enhancement of 
Rta transactivation efficiency could be aided by Pin1’s function with  RNAP II in transcriptional 
elongation or termination, or in posttranscriptional processing and splicing [128,137]. These 
functions, especially the latter, could cooperate with Mta. Like Pin1, Mta is enriched at nuclear 
speckles and is involved in posttranscriptional elongation and cellular factor-dependent viral 
pre-mRNA splicing [95,96,184]. Mta also stabilizes nascent viral transcripts and facilitates export 
of intronless viral transcripts, which account for ~70% of all KSHV mRNAs [95,96,184]. Pin1 and 
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Mta could together coordinate RNAP II transcriptional progression in conjunction with processing 
factors stored in nuclear speckles, with Mta and Pin1 first directly enhancing Rta function at 
promoters, followed by Mta stabilizing elongating transcripts, Pin1 enabling proper termination 
via CTD code modification and then Mta shuttling intronless mRNAs out of the nucleus for 
efficient translation. Taken together, along with the context-dependent Pin1 motifs scenario, Pin1 
could be part of a multi-tiered regulatory loop consisting of different functional consequences for 
Rta expression and for Rta transactivation.  
4.3. Pin1 Enhances KSHV Lytic DNA Replication 
Results from our report also suggested that inhibition of Pin1 drastically reduces the rate of 
replication as it proceeds through the lytic cycle. This could simply be due to functional carryover 
from reduced DE gene synthesis. However, the strong impact of juglone on replication suggests that 
loss of Pin1 may have a broader effect than transactivation alone. We can further suggest, then, that 
Pin1’s transactivation enhancement of Rta could extend to Rta’s association at oriLyts and its role in 
lytic replication in concert with K-bZIP [7,37,61]. Pin1 binding to Rta could enhance Rta’s ability to 
recognize its elements at oriLyts, to recruit basal DNA replication factors in a manner analogous to 
Rta’s recruitment of transcription factors at viral promoters, or to interact with K-bZIP directly. Pin1’s 
effects on Rta-mediated transactivation and replication are probably based on a single modification 
that simultaneously enhances both processes, although additional work will need to be done to rule out 
a more complex regulatory mechanism.  
4.4. Pin1 Represses KSHV Late Gene Expression and Virion Production 
We expected Pin1 to continue to act as an Rta enhancer and upregulate productive lytic reactivation 
as assessed by release of infectious virus, which often positively correlates to viral replication. Instead, 
data from our report strongly suggested that Pin1 inhibits virion production [166]. Rather than acting 
as a positive cofactor that enhances Rta-mediated transactivation and replication, Pin1 may actually be 
a complex, bimodal regulator of lytic reactivation, as it later acts as a negative cofactor that represses 
virion production and release. 
A number of potential hypotheses could be proposed that address the manner in which Pin1 inhibits 
late gene synthesis following Pin1’s enhancement of viral DNA replication. Pin1, despite its oncogenic 
functions, also has interactions with a variety of cellular or viral regulators that could negatively 
impact lytic cycle progression. One intriguing explanation for Pin1’s repression of late gene synthesis 
comes from its potential cooperation, as discussed above, with Mta during posttranscriptional and 
splicing regulation. Mta binds to intronless viral mRNA for efficient export into the cytosol for 
translation [95,96]. The cellular polyadenylation-binding protein C1 (PABPC1), with a natural 
localization in the cytosol, protects polyA transcripts from cytidine deadenylases with nanomolar 
affinity and enhances both mRNA nuclear export and translational initiation [60,96]. Upon expression 
of the lytic cycle, viral shutoff exonuclease (vSOX) relocalizes PABPC1 to the nucleus, where it binds 
and stabilizes cellular and viral polyA mRNA as before, but sequesters these transcripts in the nucleus 
[60,96]. As Mta binding to intronless viral mRNA cannot overcome PABPC1 sequestration, this 
would, in effect, shut down all polyA transcript export and translation (which, recall, accounts for 70% 
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of all viral mRNA) [60,96]. However, nut-1/PAN, the DE noncoding transcript (at 500,000 copies per 
virally-reactivated PEL cell, by far the most abundant, at upward of 80% of all cellular polyA mRNA), 
has been found to bind to PABPC1 and titrate the protein away from polyA mRNA; since Mta binds 
only intronless viral mRNAs, it was hypothesized that the cooperation of both nut-1 and Mta allows 
for preferential nuclear export of viral transcripts, while PABPC1 still drastically slows the export of 
cellular transcripts [59,60,96]. Thus, the vast majority of protein produced during lytic reactivation is 
viral. Notably, however, the loss of nut-1 accumulation has been observed to cause deficient late gene 
synthesis, with concomitant loss of virion production, even despite normal Rta expression, 
transactivation and viral DNA replication [60].  
As Pin1 is involved in many of the same processes as Mta, one could postulate that Pin1 may 
interfere in some way with PABPC1 protein interaction with nut-1 in the nucleus following vSOX 
activation; this would achieve the same functional result as nut-1 deficiency, since inhibition of nut-1 
expression does not appear to occur based on our transactivation and DE gene expression-based data. 
This modulation of nut-1 would prevent late gene synthesis without impacting any previous lytic cycle 
stage nor the suppression of cellular gene translation. The scenario also allows for a much simpler 
mechanism of bimodal Pin1 function without the requirement for any direct, mid-lytic cycle regulatory 
alteration of Pin1 activity, although combinatorial Pin1 binding to Rta could very well still occur. 
Nevertheless, Pin1’s dynamic regulation could be “built in” to the lytic cycle program, one in which 
enactment of a single modification for each of a limited number of viral factors, particularly Rta, could 
achieve a complex, tightly-coordinated progression of events. Accounting for such stage-specificity, 
Pin1 blockade of late gene synthesis following Rta induction could be due to potential time-dependent 
cofactors, such as particular DE protein interaction with Pin1; unknown differences at late gene 
promoters that prohibit Rta transactivation in concert with Pin1; upregulation of cellular or viral 
factors following the onset or completion of viral DNA replication; or aforementioned combinatorial 
Pin1 activity that directly affects Rta function.  
4.5. Molecular Timing Model for Pin1’s Effects on KSHV Replication and Pathogenesis 
Taking the culmination of results from our report together, each of the above possibilities could 
allow for Pin1 to function in a divergent manner as a postreplication lytic cycle inhibitor capable of 
reducing the efficiency of, or altogether counteracting, prolonged virion release and cell lysis. Put 
another way, Pin1 is co-opted by KSHV to regulate the timeframe of reactivation and the balance 
between abortive and productive lytic reactivation. Pin1 overexpression may shift this balancing act in 
favor of repression, while too weak Pin1 signaling might not activate Rta expression to begin with. 
Thus, a “Goldilocks” level of Pin1 regulatory activity during the lytic cycle may be required for the 
cycle’s initiation, progression and completion, a role that possibly evolved as a prosurvival, 
immunoevasive measure that emphasizes DE gene expression and clandestine viral replication within 
an infected cell population.  
This was in keeping with a dosage-dependent timing mechanism that may allow for only a subset of 
cells induced for Rta expression to advance through the full lytic cycle. Indeed, reactivation occurs in a 
small subpopulation of KSHV-infected tumor cells, produces oncogenic DE gene products that are 
believed to be essential for tumor growth and is governed by inefficient Rta activity as the vast 
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majority of Rta-expressing cells do not coexpress late gene markers, such as K8.1 [4,7,50]. Molecular 
hijacking of a conserved cellular timer that has subtle, but powerful effects on a variety of oncogenic 
and pro-viral processes could have evolved as a protective rheostat that minimizes noise for lytic 
switch induction. Fine-tuning the ratios between latency, and abortive and productive replication, 
could mitigate spurious and potentially self-limiting “runaway” virion production, host cell lysis and 
immune system activation that disrupt the local infected cell microenvironment, prevent longterm 
cellular stability of viral episomes and risk overall virus survival in the host.  
We proposed a dynamic molecular timing model in which Pin1 upregulates Rta expression, 
transactivation and viral replication ab initio, but then later suppresses optimal, productive lytic 
replication (Figure 6). If proven correct, by opening up a threshold- or kinetics-dependent “window” 
that licenses the initiation and progression of reactivation, KSHV has evolved an exquisitely balanced, 
prosurvival lytic program: co-option of a multifunctional cellular timer, Pin1 isomerase, maximizes 
Rta-mediated transactivation of viral lytic cycle genes, and then conversely protects against unchecked 
infectious virion production that would otherwise compromise host cell integrity and viral immune 
evasion for the vast majority of KSHV-infected cells that may reside within tumors. Our findings 
therefore point to Pin1 as an attractive antiherpesviral drug candidate that could be of potentially 
efficacious use in the treatment of HIV-1-positive and immunocompromised patients at risk for, or 
afflicted with, KSHV-derived malignancies. 
 
 
Figure 6. Pin1 acts a novel KSHV lytic cycle timer through regulation of Rta expression 
and downstream activity. Disease models of cells infected with latent KSHV show that a 
small subpopulation undergo reactivation, which is thought to promote tumor growth. The 
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lytic cycle cascade begins with Rta and other immediate-early (IE) protein expression, 
followed by Rta-mediated transactivation of delayed-early (DE) genes, such as Mta, and 
which include DE oncoproteins and viral DNA replication factors. Upon completion of 
Rta-dependent viral replication, late gene synthesis proceeds with structural and 
glycoprotein expression, such as K8.1. Finally, assembly and egress of infectious virions 
allows for dissemination within the host and to other individuals. It is likely that Pin1 
isomerase modulates Rta activity during reactivation. During early reactivation events (Rta 
DE transactivation, viral replication), Pin1 strongly enhances Rta function. However, by an 
unknown mechanism within the lytic cascade, Pin1 transitions into an inhibitor of late 
events (late gene synthesis, infectious virus release), halting productive reactivation. Thus, 
Pin1 functions as a molecular timer. Pin1 is known to control strength and duration of an 
array of normal and pathological cellular signals, and we believe Pin1's timing activity is 
co-opted by KSHV to allow for an evolutionarily-advantageous, nonproductive window 
allowing for DE gene expression while protecting against cell lysis and immune response 
activation. Figure modified from [166]. 
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